Category: Drugs and Pharmaceuticals
-
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
freeNewsArticles Story Summary: SAN MARINO, Calif. – Nov. 5 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G…
-
OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
freeNewsArticles Story Summary: RICHMOND, Texas – Oct. 11 (SEND2PRESS NEWSWIRE) — OCuSOFT Inc., producer of the popular ocular-lid hygiene products, OCuSOFT(R) Lid Scrub(TM) and OCuSOFT(R) Lid Scrub(TM) PLUS, is responding to a recent advertisement released by Advanced Vision Research (AVR) that was found to be misleading.
-
Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product
freeNewsArticles Story Summary: RICHMOND, Texas – Aug. 6 (SEND2PRESS NEWSWIRE) — CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.
-
U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas – New Clintelligence(R) Alignment Module Advances Global Management
freeNewsArticles Story Summary: KENILWORTH, N.J. – June 12 (SEND2PRESS NEWSWIRE) — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.
-
News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
freeNewsArticles Story Summary: SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour – published in the June issue…
-
Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
freeNewsArticles Story Summary: SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United…
-
Drug Development Costs Exceed $802 Million: Global Pharmas Use Clintelligence to Do Something About It
freeNewsArticles Story Summary: KENILWORTH, N.J. – May 2, 2007 (SEND2PRESS NEWSWIRE) — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence – 3C Company’s Business Intelligence Solution for strategic and tactical oversight…
-
Tired… Distressed… Unhappy? All Natural ‘Feel Good’ Pill Strikes a Chord with Millions of Women
freeNewsArticles Story Summary: SALT LAKE CITY, Utah – Apr. 26 (SEND2PRESS NEWSWIRE) — This provocative opening line from a television commercial for a ‘mood elevating’ pill has really struck a nerve. If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts…
-
Updated: Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G as Treatment for Diverse Metastatic Cancers
freeNewsArticles Story Summary: SAN MARINO, Calif. and TOKYO, Japan – Dec. 6, 2006 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G(TM) in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in…
-
Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G(TM) as Treatment for Diverse Metastatic Cancers
freeNewsArticles Story Summary: SAN MARINO, Calif. and TOKYO, Japan – Dec. 6 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October,…